 Leukemia, Myelogenous, Chronic, BCR-ABL Positive
"Leukemia, Myelogenous, Chronic, BCR-ABL Positive" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
| Descriptor ID |
D015464
|
| MeSH Number(s) |
C04.557.337.539.250 C15.378.190.636.370
|
| Concept/Terms |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Chronic Myelogenous
- Leukemia, Chronic Myeloid
- Leukemia, Granulocytic, Chronic
- Leukemia, Myelocytic, Chronic
- Leukemia, Myelogenous, Chronic
- Leukemia, Myelogenous, Ph1 Positive
- Leukemia, Myelogenous, Ph1-Positive
- Leukemia, Myeloid, Chronic
- Leukemia, Myeloid, Ph1 Positive
- Leukemia, Myeloid, Ph1-Positive
- Leukemia, Myeloid, Philadelphia Positive
- Leukemia, Myeloid, Philadelphia-Positive
- Myelocytic Leukemia, Chronic
- Chronic Myelocytic Leukemia
- Chronic Myelocytic Leukemias
- Leukemia, Chronic Myelocytic
- Leukemias, Chronic Myelocytic
- Myelocytic Leukemias, Chronic
- Myelogenous Leukemia, Chronic
- Chronic Myelogenous Leukemia
- Chronic Myelogenous Leukemias
- Leukemias, Chronic Myelogenous
- Myelogenous Leukemias, Chronic
- Myelogenous Leukemia, Ph1-Positive
- Leukemia, Ph1-Positive Myelogenous
- Leukemias, Ph1-Positive Myelogenous
- Myelogenous Leukemia, Ph1 Positive
- Myelogenous Leukemias, Ph1-Positive
- Ph1-Positive Myelogenous Leukemia
- Ph1-Positive Myelogenous Leukemias
- Myeloid Leukemia, Chronic
- Chronic Myeloid Leukemia
- Chronic Myeloid Leukemias
- Leukemias, Chronic Myeloid
- Myeloid Leukemias, Chronic
- Myeloid Leukemia, Ph1-Positive
- Leukemia, Ph1-Positive Myeloid
- Leukemias, Ph1-Positive Myeloid
- Myeloid Leukemia, Ph1 Positive
- Myeloid Leukemias, Ph1-Positive
- Ph1-Positive Myeloid Leukemia
- Ph1-Positive Myeloid Leukemias
- Myeloid Leukemia, Philadelphia-Positive
- Leukemia, Philadelphia-Positive Myeloid
- Leukemias, Philadelphia-Positive Myeloid
- Myeloid Leukemia, Philadelphia Positive
- Myeloid Leukemias, Philadelphia-Positive
- Philadelphia-Positive Myeloid Leukemia
- Philadelphia-Positive Myeloid Leukemias
- Granulocytic Leukemia, Chronic
- Chronic Granulocytic Leukemia
- Chronic Granulocytic Leukemias
- Granulocytic Leukemias, Chronic
- Leukemia, Chronic Granulocytic
- Leukemias, Chronic Granulocytic
|
Below are MeSH descriptors whose meaning is more general than "Leukemia, Myelogenous, Chronic, BCR-ABL Positive".
Below are MeSH descriptors whose meaning is more specific than "Leukemia, Myelogenous, Chronic, BCR-ABL Positive".
This graph shows the total number of publications written about "Leukemia, Myelogenous, Chronic, BCR-ABL Positive" by people in this website by year, and whether "Leukemia, Myelogenous, Chronic, BCR-ABL Positive" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 | | 1996 | 0 | 1 | 1 | | 1997 | 0 | 1 | 1 | | 1998 | 0 | 1 | 1 | | 2001 | 1 | 0 | 1 | | 2003 | 2 | 1 | 3 | | 2004 | 1 | 2 | 3 | | 2005 | 1 | 1 | 2 | | 2006 | 2 | 0 | 2 | | 2007 | 5 | 1 | 6 | | 2008 | 1 | 1 | 2 | | 2009 | 4 | 3 | 7 | | 2010 | 5 | 0 | 5 | | 2011 | 2 | 1 | 3 | | 2012 | 3 | 0 | 3 | | 2013 | 2 | 0 | 2 | | 2014 | 5 | 0 | 5 | | 2015 | 1 | 1 | 2 | | 2016 | 3 | 1 | 4 | | 2017 | 0 | 1 | 1 | | 2018 | 5 | 1 | 6 | | 2019 | 2 | 1 | 3 | | 2020 | 1 | 0 | 1 | | 2021 | 1 | 0 | 1 | | 2022 | 1 | 0 | 1 | | 2024 | 2 | 0 | 2 | | 2025 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Leukemia, Myelogenous, Chronic, BCR-ABL Positive" by people in Profiles.
-
Kuznetsova V, Krishnan V, Costa A, Ren X, Ricketts TD, Patel SB, Connelly AN, Goel P, Knapp JP, Franceski AM, Luca F, Lobo de Figueiredo-Pontes L, Bhatia R, Prabhakar S, Ong ST, Welner RS. Chronic inflammation deters natural killer cell fitness and cytotoxicity in myeloid leukemia. Blood Adv. 2025 Feb 25; 9(4):759-773.
-
Minhajuddin M, Winters A, Ye H, Pei S, Stevens B, Gillen A, Engel K, Gipson S, Ransom M, Amaya M, Inguva A, Gasparetto M, Althoff MJ, Miller R, Shelton I, Tolison H, Krug A, Culp-Hill R, D'Alessandro A, Sherbenou DW, Pollyea DA, Smith C, Jordan CT. Lysosomal acid lipase A modulates leukemia stem cell response to venetoclax/tyrosine kinase inhibitor combination therapy in blast phase chronic myeloid leukemia. Haematologica. 2025 Jan 01; 110(1):103-116.
-
Shah NP, Bhatia R, Altman JK, Amaya M, Begna KH, Berman E, Chan O, Clements J, Collins RH, Curtin PT, DeAngelo DJ, Drazer M, Maness L, Metheny L, Mohan S, Moore JO, Oehler V, Pratz K, Pusic I, Rose MG, Shomali W, Smith BD, Styler M, Talpaz M, Tanaka TN, Tantravahi S, Thompson J, Tsai S, Vaughn J, Welborn J, Yang DT, Sundar H, Gregory K. Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024 02; 22(1):43-69.
-
Chimge NO, Chen MH, Nguyen C, Zhao Y, Wu X, Gonzalez PG, Ogana H, Hurwitz S, Teo JL, Chen X, Du J, Jin V, Kim YM, Ono M, Argüello RJ, Kahn M. A Deeply Quiescent Subset of CML LSC depend on FAO yet Avoid Deleterious ROS by Suppressing Mitochondrial Complex I. Curr Mol Pharmacol. 2024; 17:e060923220758.
-
Patel SB, Kuznetsova V, Matkins VR, Franceski AM, Bassal MA, Welner RS. Ex Vivo Expansion of Phenotypic and Transcriptomic Chronic Myeloid Leukemia Stem Cells. Exp Hematol. 2022 11; 115:1-13.
-
Patel SB, Nemkov T, Stefanoni D, Benavides GA, Bassal MA, Crown BL, Matkins VR, Camacho V, Kuznetsova V, Hoang AT, Tenen DE, Wolock SL, Park J, Ying L, Yue Z, Chen JY, Yang H, Tenen DG, Ferrell PB, Lu R, Darley-Usmar V, D'Alessandro A, Bhatia R, Welner RS. Metabolic alterations mediated by STAT3 promotes drug persistence in CML. Leukemia. 2021 12; 35(12):3371-3382.
-
Kondapalli L, Worth S, Hawi R, Vachhani P, Arora G, Bhatia R, Lenneman CG. Collaborative cardiovascular management of patients with chronic myeloid leukemia on tyrosine kinase inhibitors. Vasc Med. 2020 06; 25(3):246-254.
-
Banegas MP, Rivera DR, O'Keeffe-Rosetti MC, Carroll NM, Pawloski PA, Tabano DC, Epstein MM, Yeung K, Hornbrook MC, Lu C, Ritzwoller DP. Long-Term Patterns of Oral Anticancer Agent Adoption, Duration, and Switching in Patients With CML. J Natl Compr Canc Netw. 2019 10 01; 17(10):1166-1172.
-
Calizo RC, Bhattacharya S, van Hasselt JGC, Wei C, Wong JS, Wiener RJ, Ge X, Wong NJ, Lee JJ, Cuttitta CM, Jayaraman G, Au VH, Janssen W, Liu T, Li H, Salem F, Jaimes EA, Murphy B, Campbell KN, Azeloglu EU. Disruption of podocyte cytoskeletal biomechanics by dasatinib leads to nephrotoxicity. Nat Commun. 2019 05 03; 10(1):2061.
-
Flynn KE, Mauro MJ, George G, Hinman A, Baim A, Kota V, Larson RA, Lipton JH, Thompson JE, Wadleigh M, Atallah E. Patients' perspectives on the definition of cure in chronic myeloid leukemia. Leuk Res. 2019 05; 80:40-42.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|